open access

Vol 71, No 2 (2020)
Review Article
Published online: 2020-04-29
Submitted: 2019-12-08
Accepted: 2020-02-02
Get Citation

Thyroid dysfunction in patients with diabetic retinopathy

Magdalena M. Stefanowicz-Rutkowska, Angelika Baranowska-Jurkun, Wojciech Matuszewski, Elżbieta M. Bandurska-Stankiewicz
DOI: 10.5603/EP.a2020.0013
·
Pubmed: 32396211
·
Endokrynologia Polska 2020;71(2):176-183.

open access

Vol 71, No 2 (2020)
Review Article
Published online: 2020-04-29
Submitted: 2019-12-08
Accepted: 2020-02-02

Abstract

Thyroid disease and diabetes mellitus (DM) are the most common endocrinopathies in clinical practice that interact with each other. On the one hand, thyroid hormones regulate carbohydrate metabolism and pancreas functions, and on the other hand DM affects the function and work of the thyroid gland. Diabetic retinopathy (DR) is a highly specific neurovascular complication of both type 1 and type 2 DM, which is a significant cause of vision loss on a global scale. In DM, the internal blood-retinal barrier is the earliest to be damaged, and changes in neuroretina result from the loss of its adaptation to metabolic disorders. Patients with DM have a higher incidence of thyroid disease compared to people without DM. The coexistence of DM with thyroid disease leads to endothelial damage, and the degree of its dysfunction has a significant impact on the course of macro- and microangiopathic complications in patients. There are few reports in the literature about the impact of thyroid disease and substitution of levothyroxine preparations on the development and course of DR in patients with DM. It is unknown whether the fact that patients with unrecognised hypothyroidism are not treated with levothyroxine preparations disrupts thyroid hormone homeostasis to the extent that it may contribute to a higher incidence of DR. This review discusses recent clinical trials for thyroid dysfunction in patients with DR. 

Abstract

Thyroid disease and diabetes mellitus (DM) are the most common endocrinopathies in clinical practice that interact with each other. On the one hand, thyroid hormones regulate carbohydrate metabolism and pancreas functions, and on the other hand DM affects the function and work of the thyroid gland. Diabetic retinopathy (DR) is a highly specific neurovascular complication of both type 1 and type 2 DM, which is a significant cause of vision loss on a global scale. In DM, the internal blood-retinal barrier is the earliest to be damaged, and changes in neuroretina result from the loss of its adaptation to metabolic disorders. Patients with DM have a higher incidence of thyroid disease compared to people without DM. The coexistence of DM with thyroid disease leads to endothelial damage, and the degree of its dysfunction has a significant impact on the course of macro- and microangiopathic complications in patients. There are few reports in the literature about the impact of thyroid disease and substitution of levothyroxine preparations on the development and course of DR in patients with DM. It is unknown whether the fact that patients with unrecognised hypothyroidism are not treated with levothyroxine preparations disrupts thyroid hormone homeostasis to the extent that it may contribute to a higher incidence of DR. This review discusses recent clinical trials for thyroid dysfunction in patients with DR. 

Get Citation

Keywords

thyroid disease; diabetes mellitus; diabetic retinopathy

About this article
Title

Thyroid dysfunction in patients with diabetic retinopathy

Journal

Endokrynologia Polska

Issue

Vol 71, No 2 (2020)

Pages

176-183

Published online

2020-04-29

DOI

10.5603/EP.a2020.0013

Pubmed

32396211

Bibliographic record

Endokrynologia Polska 2020;71(2):176-183.

Keywords

thyroid disease
diabetes mellitus
diabetic retinopathy

Authors

Magdalena M. Stefanowicz-Rutkowska
Angelika Baranowska-Jurkun
Wojciech Matuszewski
Elżbieta M. Bandurska-Stankiewicz

References (85)
  1. Mamun M, Nahar N, Salekin M, et al. Thyroid Hormonal Status in Newly Diagnosed Type 2 Diabetes Mellitus. Bangl J Nucl Med. 2018; 20: 1–27.
  2. Nishi M. Diabetes mellitus and thyroid diseases. Diabetol Int. 2018; 9(2): 108–112.
  3. Donckier JE. Endocrine diseases and diabetes. In: Pickup JC, Williams G. ed. Diabetes Mellitus. Blackwell Publishing Company, Chichester 2003: 21–27.
  4. Biondi B, Kahaly GJ, Robertson RP. Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders. Endocr Rev. 2019; 40(3): 789–824.
  5. Chutia H, Bhattacharyya H, Ruram AA, et al. Evaluation of thyroid function in type 2 diabetes in north-eastern part of India: A hospital-based study. J Family Med Prim Care. 2018; 7(4): 752–755.
  6. Chawla A, Chawla R, Jaggi S. Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum? Indian J Endocrinol Metab. 2016; 20(4): 546–551.
  7. Solomon SD, Chew E, Duh EJ, et al. Diabetic Retinopathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017; 40(3): 412–418.
  8. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetologia Praktyczna. 2018; 4(1): 1–94.
  9. Sheldon J. Laboratory testing in autoimmune rheumatic diseases. Best Pract Res Clin Rheumatol. 2004; 18(3): 249–269.
  10. McCoy L, Tsunoda I, Fujinami RS. Multiple sclerosis and virus induced immune responses: autoimmunity can be primed by molecular mimicry and augmented by bystander activation. Autoimmunity. 2006; 39(1): 9–19.
  11. Guilherme L, Kalil J. Rheumatic fever: the T cell response leading to autoimmune aggression in the heart. Autoimmun Rev. 2002; 1(5): 261–266.
  12. Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of autoimmune disease. Autoimmun Rev. 2012; 11(10): 754–765.
  13. Sfriso P, Ghirardello A, Botsios C, et al. Infections and autoimmunity: the multifaceted relationship. J Leukoc Biol. 2010; 87(3): 385–395.
  14. Desai MK, Brinton RD. Autoimmune Disease in Women: Endocrine Transition and Risk Across the Lifespan. Front Endocrinol (Lausanne). 2019; 10: 265.
  15. Golden SH, Robinson KA, Saldanha I, et al. Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review. J Clin Endocrinol Metab. 2009; 94(6): 1853–1878.
  16. Iddah MA, Macharia BN. Autoimmune thyroid disorders. ISRN Endocrinol. 2013; 2013: 509764.
  17. Sawicka-Gutaj N, Zybek-Kocik A, Klimowicz A, et al. Circulating Visfatin in Hypothyroidism Is Associated with Free Thyroid Hormones and Antithyroperoxidase Antibodies. Int J Endocrinol. 2016; 2016: 7402469.
  18. Delemer B, Aubert JP, Nys P, et al. An observational study of the initial management of hypothyroidism in France: the ORCHIDÉE study. Eur J Endocrinol. 2012; 167(6): 817–823.
  19. Caturegli P, De Remigis A, Rose NR. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. 2014; 13(4-5): 391–397.
  20. Bloodworth J. Diabetic retinopathy. Diabetes. 1962; 11: 1–22.
  21. Wolter JR. Diabetic retinopathy. Am J Ophthalmol. 1961; 51: 1123–1141.
  22. Cunha-Vaz J. Neurodegeneration as an early event in the pathogenesis of Diabetic Retinopathy: A multicentric, prospective, phase II-III, randomised controlled trial to assess the efficacy of neuroprotective drugs administered topically to prevent or arrest Diabetic Rethinopathy. EUROCONDOR — EU FP7 Project. Acta Ophthalmol. 2012; 90(249): 0–0.
  23. Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012; 366(13): 1227–1239.
  24. Cunha-Vaz J, Ribeiro L, Lobo C. Phenotypes and biomarkers of diabetic retinopathy. Prog Retin Eye Res. 2014; 41: 90–111.
  25. Ratajczak W, Tokarz-Deptuła B, Deptuła W. Immunologia oka. Postepy Hig Med Dosw (online). 2018; 72: 318–325.
  26. Abcouwer SF, Gardner TW. Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment. Ann NY Acad Sci. 2014; 1311: 174–190.
  27. Sohn EH, van Dijk HW, Jiao C, et al. Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus. Proc Natl Acad Sci USA. 2016; 113(19): E2655–E2664.
  28. Eshaq RS, Aldalati AMZ, Alexander JS, et al. Diabetic retinopathy: Breaking the barrier. Pathophysiology. 2017; 24(4): 229–241.
  29. Rusin P, Majsterek I. Molekularne podstawy retinopatii cukrzycowej. Postępy Hig. Med. Dośw. (online). 2007; 61: 786–796.
  30. Yau JWY, Rogers SL, Kawasaki R, et al. Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012; 35(3): 556–564.
  31. Kollias AN, Ulbig MW. Diabetic retinopathy: Early diagnosis and effective treatment. Dtsch Arztebl Int. 2010; 107(5): 75–83; quiz 84.
  32. Wu L, Fernandez-Loaiza P, Sauma J, et al. Classification of diabetic retinopathy and diabetic macular edema. World J Diabetes. 2013; 4(6): 290–294.
  33. Fong DS, Aiello L, Gardner TW, et al. Diabetic Retinopathy. Diabetes Care. 2003; 26(Supplement 1): S99–S102.
  34. Rajalakshmi R, Prathiba V, Mohan V. Does tight control of systemic factors help in the management of diabetic retinopathy? Indian J Ophthalmol. 2016; 64(1): 62–68.
  35. Pradeepa R, Anitha B, Mohan V, et al. Risk factors for diabetic retinopathy in a South Indian Type 2 diabetic population — the Chennai Urban Rural Epidemiology Study (CURES) Eye Study 4. Diabet Med. 2008; 25(5): 536–542.
  36. Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000; 23(Suppl 2): B21–B29.
  37. Chew EY, Ambrosius WT, Davis MD, et al. ACCORD Study Group, ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010; 363(3): 233–244.
  38. Nathan DM, Genuth S, Lachin J, et al. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14): 977–986.
  39. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131): 837–853.
  40. Matuszewski W, Bandurska-Stankiewicz E, Modzelewski R, et al. Diagnosis and treatment of diabetic retinopathy — historical overview. Clin Diab. 2017; 6(5): 182–188.
  41. Silva PS, Cavallerano JD, Sun JK, et al. Effect of systemic medications on onset and progression of diabetic retinopathy. Nat Rev Endocrinol. 2010; 6(9): 494–508.
  42. Kozak I, Luttrull JK. Modern retinal laser therapy. Saudi J Ophthalmol. 2015; 29(2): 137–146.
  43. Yun SH, Adelman RA. Recent developments in laser treatment of diabetic retinopathy. Middle East Afr J Ophthalmol. 2015; 22(2): 157–163.
  44. Zhao Y, Singh RP. The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy. Drugs Context. 2018; 7: 212532.
  45. Brănişteanu DC, Bilha A, Moraru A. Vitrectomy surgery of diabetic retinopathy complications. Rom J Ophthalmol. 2016; 60(1): 31–36.
  46. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012; 15(2): 171–185.
  47. Hage M, Zantout MS, Azar ST. Thyroid disorders and diabetes mellitus. J Thyroid Res. 2011; 2011: 439463.
  48. Perros P, McCrimmon RJ, Shaw G, et al. Frequency of thyroid dysfunction in diabetic patients: value of annual screening. Diabet Med. 1995; 12(7): 622–627.
  49. Hansen D, Bennedbaek FN, Hansen LK, et al. Thyroid function, morphology and autoimmunity in young patients with insulin-dependent diabetes mellitus. Eur J Endocrinol. 1999; 140(6): 512–518.
  50. Celani MF, Bonati ME, Stucci N. Prevalence of abnormal thyrotropin concentrations measured by a sensitive assay in patients with type 2 diabetes mellitus. Diabetes Res. 1994; 27(1): 15–25.
  51. Ray S, Ghosh S. Thyroid Disorders and Diabetes Mellitus: Double Trouble . J Dia Res Ther. 2016; 2(1).
  52. Palma CC, Pavesi M, Nogueira VG, et al. Prevalence of thyroid dysfunction in patients with diabetes mellitus. Diabetol Metab Syndr. 2013; 5(1): 58.
  53. Kordonouri O, Charpentier N, Hartmann R. GADA positivity at onset of type 1 diabetes is a risk factor for the development of autoimmune thyroiditis. Pediatr Diabetes. 2011; 12(1): 31–33.
  54. Kadiyala R, Peter R, Okosieme OE. Thyroid dysfunction in patients with diabetes: clinical implications and screening strategies. Int J Clin Pract. 2010; 64(8): 1130–1139.
  55. Ahmed A, Waris A, Naheed A, et al. Diabetic Retinopathy and its Correlation with Thyroid Profile and Anti Thyroid Antibodies. IOSR-JDMS. 2017; 16(1): 96–98.
  56. Kordonouri O, Deiss D, Danne T, et al. Predictivity of thyroid autoantibodies for the development of thyroid disorders in children and adolescents with Type 1 diabetes. Diabet Med. 2002; 19(6): 518–521.
  57. Kordonouri O, Hartmann R, Deiss D, et al. Natural course of autoimmune thyroiditis in type 1 diabetes: association with gender, age, diabetes duration, and puberty. Arch Dis Child. 2005; 90(4): 411–414.
  58. Lindberg B, Ericsson UB, Ljung R, et al. High prevalence of thyroid autoantibodies at diagnosis of insulin-dependent diabetes mellitus in Swedish children. J Lab Clin Med. 1997; 130(6): 585–589.
  59. Gursoy NT, Tuncel E. The relationship between the glycemic control and the hypothalamus–pituitary–thyroid axis in diabetic patients. Turk J Endocrinol Metab. 1999; 4: 163–168.
  60. Ortiz-Caro J, Obregón MJ, Pascual A, et al. Decreased T4 to T3 conversion in tissues of streptozotocin-diabetic rats. Acta Endocrinol (Copenh). 1984; 106(1): 86–91.
  61. Bagchi N, Palaniswami N, Desai H, et al. Decreased thyroidal response to thyrotropin in type II diabetes mellitus. Metabolism. 1988; 37(7): 669–671.
  62. Rezzonico J, Rezzonico M, Pusiol E, et al. Introducing the thyroid gland as another victim of the insulin resistance syndrome. Thyroid. 2008; 18(4): 461–464.
  63. Ayturk S, Gursoy A, Kut A, et al. Metabolic syndrome and its components are associated with increased thyroid volume and nodule prevalence in a mild-to-moderate iodine-deficient area. Eur J Endocrinol. 2009; 161(4): 599–605.
  64. Chutia H, Bhattacharyya H, Ruram AA, et al. Evaluation of thyroid function in type 2 diabetes in north-eastern part of India: A hospital-based study. J Family Med Prim Care. 2018; 7(4): 752–755.
  65. Martino E, Seo H, Lernmark A, et al. Ontogenetic patterns of thyrotropin-releasing hormone-like material in rat hypothalamus, pancreas, and retina: selective effect of light deprivation. Proc Natl Acad Sci USA. 1980; 77(7): 4345–4348.
  66. Mendoza A, Hollenberg AN. New insights into thyroid hormone action. Pharmacol Ther. 2017; 173: 135–145.
  67. Pinazo-Durán MD, Pons-Vázquez S, Gallego-Pinazo R, et al. Thyroid hormone deficiency disrupts rat eye neurodevelopment. Brain Res. 2011; 1392: 16–26.
  68. Kocaturk T, Ergin K, Cesur G, et al. The effect of methimazole-induced postnatal hypothyroidism on the retinal maturation and on the Sirtuin 2 level. Cutan Ocul Toxicol. 2016; 35(1): 36–40.
  69. Waber S, Meister V, Rossi GL, et al. Studies on retinal microangiopathy and coronary macroangiopathy in rats with streptozotocin-induced diabetes. Virchows Arch B Cell Pathol Incl Mol Pathol. 1981; 37(1): 1–10.
  70. Takiguchi Y, Satoh N, Hashimoto H, et al. Reversal effect of thyroxine on altered vascular reactivity in diabetic rats. J Cardiovasc Pharmacol. 1989; 13(4): 520–524.
  71. Ittermann T, Dörr M, Völzke H, et al. High serum thyrotropin levels are associated with retinal arteriolar narrowing in the general population. Thyroid. 2014; 24(10): 1473–1478.
  72. Czarnywojtek A, Owecki M, Zgorzalewicz-Stachowiak M, et al. The role of serum C-reactive protein measured by high-sensitive method in thyroid disease. Arch Immunol Ther Exp (Warsz). 2014; 62(6): 501–509.
  73. Iitaka M, Miura S, Yamanaka K, et al. Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves' disease and Hashimoto's thyroiditis. J Clin Endocrinol Metab. 1998; 83(11): 3908–3912.
  74. Kajdaniuk D, Marek B, Foltyn W, et al. Vascular endothelial growth factor (VEGF) — part 2: in endocrinology and oncology. Endokrynol Pol. 2011; 62(5): 456–464.
  75. Rizos CV, Elisaf MS, Liberopoulos EN. Effects of thyroid dysfunction on lipid profile. Open Cardiovasc Med J. 2011; 5: 76–84.
  76. Popescu T, Moţa M. Dyslipidemia and hypertension in patients with type 2 diabetes and retinopathy. Rom J Intern Med. 2009; 47(3): 235–241.
  77. Baskol G, Atmaca H, Tanriverdi F, et al. Oxidative stress and enzymatic antioxidant status in patients with hypothyroidism before and after treatment. Exp Clin Endocrinol Diabetes. 2007; 115(8): 522–526.
  78. Rodacki M, Zajdenverg L, Dantas JR, et al. Should thyroid-stimulating hormone goals be reviewed in patients with type 1 diabetes mellitus? Results from the Brazilian Type 1 Diabetes Study Group. Diabet Med. 2014; 31(12): 1665–1672.
  79. Rogowicz-Frontczak A, Pilacinski S, Chwialkowska AT, et al. Patients with diabetes type 1 and thyroid autoimmunity have low prevalence of microangiopathic complications. Endocrine. 2016; 51(1): 185–188.
  80. Glastras SJ, Craig ME, Verge CF, et al. The role of autoimmunity at diagnosis of type 1 diabetes in the development of thyroid and celiac disease and microvascular complications. Diabetes Care. 2005; 28(9): 2170–2175.
  81. Schneider T, Meyerson L. Thyroid therapy in diabetic retinopathy. S Afr Med J. 1969; 43(14): 414–417.
  82. Sailesh S. The THOR Effect: Thyroid Hormone Offsets Retinopathy. J Endocrinol Thyroid Res. 2018; 3(1): 555605.
  83. Wu J, Yue S, Geng J, et al. Relationship between Diabetic Retinopathy and Subclinical Hypothyroidism: a meta-analysis. Sci Rep. 2015; 5: 12212.
  84. Borooah M, Phukan S. A study on relationship between severity of diabetic retinopathy and subclinical hypothyroidism. Int J Res Med Sci. 2017; 5(5): 1818–1822.
  85. Porta M, Sjoelie AK, Chaturvedi N, et al. EURODIAB Prospective Complications Study Group. Risk factors for progression to proliferative diabetic retinopathy in the EURODIAB Prospective Complications Study. Diabetologia. 2001; 44(12): 2203–2209.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl